D. Boyer

Ophthalmology · Ophthalmology (Rochester, Minn.) · 2006–2014

A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom D. Boyer trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. David M. Brown
  2. K. Eng

Papers from D. Boyer's perspective

Ordered by how strongly the researchers D. Boyer trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (New England Journal of Medicine)
  2. Diabetic macular edema: pathogenesis and treatment. (Survey of ophthalmology)
  3. Ranibizumab in neovascular age-related macular degeneration (Clinical Interventions in Aging)
  4. DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (Retina)
  5. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration (New England Journal of Medicine)
  6. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. (Ophthalmology (Rochester, Minn.))
  7. Pegaptanib for neovascular age-related macular degeneration. (New England Journal of Medicine)
  8. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. (American journal of ophthalmology-glaucoma)
  9. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  10. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Their papers